# A Study Evaluating the Efficacy and Safety of Baricitinib in Systemic Sclerosis

> **NCT05300932** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Tongji Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Systemic Sclerosis

## Interventions

- **DRUG:** Baricitinib
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT05300932
- **Lead sponsor:** Tongji Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-03-08
- **Primary completion:** 2026-08-01
- **Final completion:** 2026-11-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-01-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05300932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05300932, "A Study Evaluating the Efficacy and Safety of Baricitinib in Systemic Sclerosis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05300932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*